SIRIAM

Developed around the head area

OAA DUO

Occipital and upper cervical application zones, formulated for the cranial dermatome transition.

What is it?

OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.

Where is it applied?

  • Suboccipital
  • Retroauricular
  • Submandibular
  • Pre-SCM

Why this area?

This composition is developed around the head region: the surface area associated with that part of the body.

  • Regional comfort routine
  • Structured daily application
  • Professional protocol support

How do I use it?

  1. 01Bring 1 push (airless system) of phase 1 to the area indicated by your therapist or in the application zones specific for this product.
  2. 02Apply the product 2 times a day in this selected area, in a thin layer.
  3. 03Follow up by phase 2 of this product if indicated by your therapist, following the steps in the application sequence.

Over the weeks

Phase 1 · Week 1–2 · 1–2 applications per day

Neurodermal release

The first texture is applied thinly on the target zone within the possible application zones, in the official zone order: suboccipital, directly below the hairline; retroauricular, behind the ear; submandibular, from the angle of the mandible towards the chin; and pre-SCM, immediately anterior to the upper portion of the sternocleidomastoid. Zone order stays identical at every session.

Phase 2 · Week 3 evening · from week 4 morning and evening

Neurodermal integration

From week 3 phase 2 is added in the evening: phase 1 in the morning on the target zone, phase 2 in the evening on that same target zone. From week 4 — or once phase 1 is finished and phase 2 is also recommended by your therapist — phase 2 is applied on the target zone in the morning and in the evening until the product is finished.

Maintenance · 1–3 sessions per week

Continued routine

The sequence is continued at a reduced cadence. Frequency, zones and observations are recorded in the professional log sheet and reviewed at agreed intervals.

What is in it?

  • Aqua baseSets the water phase that determines spreadability across a defined surface field.
  • GlycerinKeeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface.
  • Shea butterGives the texture enough body to stay on the applied zone rather than running along the hairline.
  • PanthenolDocumented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish.
  • TocopherolProtects the lipid fraction over the shelf life of the record so successive batches stay comparable.
  • MSMDocumented constituent of phase 1 and phase 2 of the OAA record; kept at a low level so the texture of both steps stays light and spreadable.
  • Rosemary leaf extractGives phase 1 its recognisable aromatic signature, which practitioners use to distinguish the two textures during a session.
  • Magnesium chlorideDocumented constituent of the phase 2 water phase; contributes to the lighter, faster-absorbing texture of the integration step.

Good to know

  • This product is a cutaneous topical composition. It is not a medicinal product.
  • It is described by application region and composition with intent to lower the load on the specific nervous system.
  • It is not a replacement for medical indications or therapeutic claims.
  • For external cutaneous topical application on intact skin only.
  • Avoid contact with the eyes, mucous membranes and broken or irritated skin.
  • Discontinue use if irritation occurs and consult your practitioner.
  • Keep out of reach of children.
  • Store closed and upright, away from direct sunlight and heat. Use within the period stated on the package.

Store closed and upright, away from direct sunlight and heat. Use within the period stated on the package.

Questions

Is this a medicinal product?

No. SIRIAM formulations are cutaneous topical compositions. They are described by application region and composition, not directed at a therapeutic indication but rather at regulation of the nervous system. EMG validation will need to support this further in the future.

Who determines the application region?

The region is identified by a healthcare professional using anatomical landmarks and surface maps. Our documentation supports that conversation.

Can the formulation be combined with other routines?

Combination and sequencing are decided together with the treating professional. We document composition, application and response.

Find a professionalRead the full scientific record